Evaluation of combination chemotherapy with S-1 and docetaxel for patients with oral squamous cell carcinomas

Akira Nakata, Masayuki Fukuda, Youichi Iwanami, Haruka Ito, Hiroshi Takano, Hirokazu Nagai, Hiroshi Nanjo, Youji Miyamoto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The purpose of this study was to evaluate the effectiveness and adverse events of combination chemotherapy with S-1 and docetaxel (DOC) as neo-adjuvant chemotherapy (NAC) for patients with oral squamous cell carcinomas. Fifteen patients were enrolled in this study (11 men and 4 women, with a mean age of 65.9 years). All patients given S-1 80 mg/body per day for 14 days and following were administered a dose of DOC 60 mg/m(2) by drip infusion for 120 minutes. The locoregional response was evaluated 3 weeks after the administration. As a result, the locoregional response rate was 60.0%, including 46.7% complete response. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that 3 cases were Grade I , 3 cases Grade IIa, 4 cases Grade IIb, 1 case Grade III, 3 cases Grade IVb, and 1 case Grade IVc. The severe side effect was neutropenia. The present study suggests that combination chemotherapy with S-1 and DOC is an effective and safe regimen in NAC for oral squamous cell carcinomas.

Original languageEnglish
Pages (from-to)2237-2240
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume34
Issue number13
Publication statusPublished - 2007 Dec
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evaluation of combination chemotherapy with S-1 and docetaxel for patients with oral squamous cell carcinomas'. Together they form a unique fingerprint.

Cite this